vimarsana.com
Home
Live Updates
ASCO 2024: Zanzalintinib (XL092) plus Nivolumab in Non-Clear Cell Renal Cell Carcinoma: The Randomized Phase 3 STELLAR-304 Study : comparemela.com
ASCO 2024: Zanzalintinib (XL092) plus Nivolumab in Non-Clear Cell Renal Cell Carcinoma: The Randomized Phase 3 STELLAR-304 Study
ASCO 2024 phase III STELLAR-304 trial, combination of zanzalintinib (XL092) plus nivolumab in patients with non-clear cell renal cell carcinoma (nccRCC), tyrosine kinase inhibitor (TKI) sunitinib.
Related Keywords
Toronto ,
Ontario ,
Canada ,
United States ,
Chicago ,
Illinois ,
American ,
America ,
Sumantak Pal ,
Sumanta Pal ,
American Society Of Clinical Oncology ,
Twitter ,
Department Of Medical Oncology ,
Society Of Urologic Oncology ,
University Of Toronto ,
Therapeutics Research ,
City Of Hope Comprehensive Cancer Center ,
Clinical Oncology ,
Annual Meeting ,
South America ,
North America ,
Medical Oncology ,
Hope Comprehensive Cancer Center ,
Rashid Sayyid ,
Urologic Oncology ,
Clinical Fellow ,
comparemela.com © 2020. All Rights Reserved.